Zevra Therapeutics, Inc. (NASDAQ:ZVRA) said EMA’s CHMP issued a negative opinion on arimoclomol for Niemann‑Pick type C and will seek CHMP re‑examination with a detailed response, while also scheduling Q2 2026 results and a 4:30 p.m. ET conference call/webcast on Aug 5, 2026.
Previous Week Recap
- Zevra Therapeutics, Inc. Negative CHMP Opinion: Zevra Therapeutics (ZVRA) said EMA’s CHMP issued a negative opinion on arimoclomol for Niemann-Pick type C; company will seek CHMP re‑examination and file a detailed response.
- Zevra Therapeutics, Inc. Q2 2026 Results: Zevra Therapeutics (ZVRA) will report Q2 2026 results after market close on Aug 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.